Our thoughts and
market intelligence.
Our thinking on the market commissioning landscape, population health and what the latest policy and commercial changes mean for pharma and med-tech teams in practice. No abstractions. No recycled news.
"Strategy is a commodity, execution is an art."
— Peter Drucker
The Brain We Are Not Talking About
At least one in six people in England lives with a neurological condition — yet the gap between the burden neurological disease places on the NHS and the commercial infrastructure built to address it remains one of the least discussed problems in UK pharma.
April 2026Read Article →
Documents & Papers
ICB Mergers, NHS England Abolished — Will Any of It Actually Fix Capacity?
42 ICBs are becoming 26. The capacity crisis is a workforce and capital problem, not a commissioning geography problem.
Smoking is Down, Gyms are Full — So Why is the Nation's Health Still Stalling?
Gym membership at a record high. GLP-1 drugs are called the most significant pharmacological advance of a generation. And physical inactivity is still responsible for five million deaths a year globally.
Prevention vs Treatment — Is the NHS 10-Year Plan's Shift Actually Working?
The direction is right. The data on CVD, diabetes, cancer, mental health and neurology tells a more complicated story.
The NHS Will Not Be Fixed in This Parliament — What Does That Mean for Your Commercial Strategy?
Government, NHS, public and industry: four parties, four responsibilities. The commercially intelligent response is not waiting for the system to sort itself out.
Are you selling clinical features or released capacity?
If your value proposition only proves efficacy, it will stall at the funding committee. Here is how to translate science into the economic language that gets a yes.
Struggling to get your commercial strategy over the line?
A solo consultant cannot hold the deep, varied expertise required to drive a complex market launch. There is a better model.
Get our thinking delivered.
Market intelligence and commercial insight for senior pharma and med-tech leaders. When we publish, you will be the first to know.
We do not share your details. Unsubscribe at any time.